Intellia Therapeutics NTLA
NASDAQ NTLA
$12.08 +0.02 (+0.17%)
As of: Oct 1, 2026 · 9:33 AM EDT

Intellia Therapeutics (NTLA) Equity Income (2021 - 2023)

Updated

Intellia Therapeutics' Equity Income came in at -$4.73 million for Q4 2023, compared with -$3.25 million a year earlier.

Analysis

Intellia Therapeutics (NTLA) Equity Income (2021 - 2023) Analysis & Trends

For FY2023, Intellia Therapeutics' Equity Income was -$15.63 million.

  • Going back by year, Equity Income was -$11.08 million in FY2022 and -$1.33 million in FY2021.
  • The Q4 2023 figure represents the lowest quarterly Equity Income in data going back to Q4 2021.
  • Business Quant data shows NTLA's Equity Income at -$3.86 million (Q3 2023), -$4 million (Q2 2023) and -$3.05 million (Q1 2023) in the three quarters before Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -10.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Intellia Therapeutics 1.69 Bn 1.69 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -4.73 Mn
Sep 30, 2023 -3.86 Mn
Jun 30, 2023 -4.00 Mn
Mar 31, 2023 -3.05 Mn
Dec 31, 2022 -3.25 Mn
Sep 30, 2022 -1.83 Mn
Jun 30, 2022 -3.25 Mn
Mar 31, 2022 -2.75 Mn
Dec 31, 2021 -1.33 Mn
API Access

Intellia Therapeutics Equity Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=equity-income&ticker=NTLA&period=max&api_key=YOUR_API_KEY